Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

Inclusion Criteria: * 18 years or older * chemotherapy naive, histologically high grade soft tissue sarcoma that is considered to be operable * tumor greater than 5 cm in longest dimension * life expectancy of at least 6 months * Zubrod performance status of 0-2 * signed informed consent * adequate bone marrow function defined by: 1. absolute peripheral granulocyte count of \>1500 cells/mm\^3 2. hemoglobin \>8.0 g/dl 3. platelet count \>100,000/mm\^3 4. absence of a regular red blood cell transfusion requirement * adequate hepatic function defined by: 1. total bilirubin \<1.5 x upper limit of normal (ULN) 2. AST, ALT and alkaline phosphatase all not more than 2.5 x ULN * adequate renal function defined by: 1\. serum creatinine \<1.5 x ULN * negative pregnancy test for women of child bearing potential * willingness to use effective contraception while on treatment and for 3 months thereafter Exclusion Criteria: * Multiple metastases (patients with 5 or fewer oligometastases that could be resectable are eligible) * Pregnant women or nursing mothers * concurrent chemotherapy or radiation therapy * severe medical problems (at the discretion of the investigator) * history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 * symptomatic brain metastases * cirrhosis * dermatofibrosarcoma protuberans (DFSP), embryonal rhabdomyosarcoma or alveolar soft part sarcoma (ASPS)